Tier 4 — mechanistic

Role of the betaine/GABA transporter (BGT-1/GAT2) for the control of epilepsy

Arne Schousboe, Orla M Larsson, Alan Sarup, H Steve White
European journal of pharmacology 2004 500(1-3):281-287

Bibliography

PubMed
PMID 15464040
DOI
10.1016/j.ejphar.2004.07.032
Funding
Indexed grant support: N01-NS-9-2313 — NINDS NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SamplePublished literature; no newly enrolled participant cohort
InterventionReview of betaine-related evidence; no single assigned intervention
DurationEvidence review; source-specific study durations vary
EndpointsBetaine biology; Clinical and mechanistic evidence

What the study showed, in plain terms

Published in 2004, this source examined mechanistic and clinical reviews. Its evidence base was Published literature; no newly enrolled participant cohort. It evaluated Review of betaine-related evidence; no single assigned intervention across Evidence review; source-specific study durations vary.

Discusses betaine/GABA transporter pharmacology as a possible route to anticonvulsant drug development.

Transporter-inhibiting drugs are different interventions from consuming betaine. This does not demonstrate TMG as an epilepsy treatment.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Discusses betaine/GABA transporter pharmacology as a possible route to anticonvulsant drug development.
  • The recorded outcome domains were Betaine biology; Clinical and mechanistic evidence.

What this study can and cannot tell us

  • Transporter-inhibiting drugs are different interventions from consuming betaine. This does not demonstrate TMG as an epilepsy treatment.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021
Tier 4
Betaine in human nutrition
Stuart A S Craig et al. · The American journal of clinical nutrition · 2004
Tier 4
Choline and betaine in health and disease
Per Magne Ueland et al. · Journal of inherited metabolic disease · 2011

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology